强化降脂治疗方案对急性脑梗死患者血脂和炎症因子水平及预后的影响

摘要

目的 观察强化降脂治疗方案对急性脑梗死(ACI)患者血脂、炎症因子水平及预后的影响.方法 将2016年1月至12月治疗的88例ACI患者作为研究对象,依照随机数表法将其分为两组,各44例.对照组采取20 mg/d阿托伐他汀治疗,观察组采取40 mg/d阿托伐他汀治疗.观察两组治疗前后血脂、炎症因子水平及不良反应发生率、预后情况.结果 治疗前,两组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平比较,差异无统计学意义(P＞0.05);治疗后,观察组TC、TG、LDIL-C、hs-CRP与TNF-α水平低于对照组,差异有统计学意义(P＜0.05);两组复发率相比,对照组高于观察组,差异有统计学意义(P＜ 0.05);两组不良反应发生率相比,差异无统计学意义(P＞0.05).结论 强化降脂治疗有助于调节ACI患者血脂、炎症因子水平,提升机体内易损斑块稳定性,降低复发风险,进而提升临床疗效与预后,安全性较高.%Objective To observe the effect of enhanced lipid lowering therapy on blood lipid,inflammatory factors,and prognosis in patients with acute cerebral infarction (ACI).Methods 88 cases of ACI from January 2016 to December 2016 were selected as the research object,and were divided into two groups according to the random number table method,44 cases in each group.The control group was treated with 20 mg/d atorvastatin,and the observation group was treated with 40 mg/d atorvastatin.The levels of blood lipids,inflammatory factors before and after the treatment,the incidence of adverse reactions,and the prognosis of the two groups were observed.Results There were no statistically significant differences in the levels of total cholesterol (TC),triacylglycerol (TG),low density lipoprotein cholesterol (LDL-C),high sensitive C reactive protein (hs-CRP),tumor necrosis factor alpha (TNF-alpha) between the two groups before treatment (P＞0.05);after treatment,the levels ofTC,TG,LDL-C,hs-CRP,and TNF-alpha of the observation group were lower than those of the control group,with statistically significant differences (P＜0.05).The recurrence rate of the control group was higher than that of the observation group,with statistically significant difference (P＜0.05).There was no statistically significant difference in the incidence of adverse effects between the two groups (P＞0.05).Conclusion Intensive lipid-lowering therapy can help to regulate the levels of blood lipids and inflammatory factors in ACI patients,enhance the stability of vulnerable plaques,reduce the risk of recurrence,and enhance the clinical efficacy and prognosis.